Table 1 Patient characteristics
Total patients | (n = 39) | |
|---|---|---|
Age | ||
≤ 69 years | 20 (51.3%) | |
> 69 years | 19 (48.7%) | |
Tumor stage | ||
cT1 | 12 (30.8%) | |
cT2 | 5 (12.8%) | |
cT3a | 13 (33.4%) | |
cT3b | 7 (17.9%) | |
cT4 | 2 (5.1%) | |
Gleason score | ||
2–6 | 20 (51.3%) | |
7 | 13 (33.3%) | |
8–10 | 6 (15.4%) | |
Pre-treatment PSA | ||
≤ 10 ng/mL | 20 (51.3%) | |
>10 ng/mL | 19 (48.7%) | |
Risk group | ||
Low | 7 (17.9%) | |
Intermediate | 8 (20.5%) | |
High | 24 (61.6%) | |
Hormonal therapy | ||
no | 10 (25.6%) | |
yes | 29 (74.4%) | |
Median FU months† (range) | 29 (22–40) | |